Mycovia tackling chronic infections with antifungal pipeline
Mycovia aims to treat chronic fungal infections with safer CYP51 inhibitors
Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections.
The company's lead product VT-1161 otesaconazole is in Phase III testing for recurrent vulvovaginal candidiasis (rVVC), a chronic yeast infection that affects about 138 million women worldwide every year.
No drugs are approved for rVVC. Acute vulvovaginal candidiasis is treated with oral or topical azole antifungals, most often fluconazole.
